MDMA and Healing a Dis-regulated Nervous System
“I have worked with a lot of medicine on my healing journey. Dozens of ayahuasca ceremonies. Extensive experience with psilocybin, ketamine, kambo, and deep sessions with 5-MeO. While I’ve had …
MDMA
First Participant Completes Treatment in Phase 2 Study at the Bronx, New York Veterans Affairs Medical Center
Enrollment is continuing for our Phase 2, open-label study on the effectiveness of MDMA-assisted therapy in U.S. Veterans with chronic PTSD. This study is a comparative study that assesses two versus three …
Social Anxiety MDMA-Assisted Therapy Investigation (SAMATI)
Jason Luoma, Ph.D., of Portland Psychotherapy, is the sponsor and Principal Investigator for SAMATI, an exploratory study to investigate the safety and preliminary efficacy of MDMA-assisted therapy for …
MDMA Therapy Training Program Update: June 2022
Training staff and contractors pictured above, from left to right: Sara Gael Giron, Corey Westbury, Veena Muthusamy, Nicole Sylvestre, Chris Stauffer, Ryan Beauregard, Wesley Hale, Christine Penny, Bruce …
The New York Times: A Balm for Psyches Scarred by War
Summary: The New York Times publishes an investigative article exploring the impact of PTSD and moral injury in Veterans, highlighting published data from MAPS-sponsored clinical trials of MDMA-assisted …
Two Expanded Access Study Sites Now Open for Enrollment
Two new study sites are now enrolling for our MDMA-assisted therapy for PTSD Expanded Access program. The Pearl Institute in Waynesville, North Carolina, and Sage Integrative Health in Berkeley, California, …
Screening Begins in Phase 2 MDMA-Assisted Therapy Study of Participants with PTSD in Berlin and London
The MAPS Europe team is delighted to announce that screening of participants for our open-label Phase 2 study of MDMA-assisted therapy for PTSD has begun at the Charité – Universitätsmedizin Berlin …
One Subject Treated, Four Subjects Evaluated in Phase 2, Open-Label, Randomized Comparative Effectiveness Study for MDMA-Assisted Therapy in U.S. Military Veterans with Chronic PTSD
As of early May, one subject has been treated and four subjects are being evaluated for treatment in the MAPS-sponsored Phase 2, open-label study of the comparative effectiveness of two vs. three MDMA-assisted …
Participant Enrolled in Phase 2, Open-Label, Randomized Comparative Effectiveness Study for MDMA-Assisted Therapy in U.S. Military Veterans with Chronic PTSD
As of April 15, 2022, the second and third participants are screening for treatment in the MAPS-sponsored Phase 2, open-label study of the comparative effectiveness of two vs. three MDMA-assisted therapy …
FDA Continues Clinical Hold for Open-Label Feasibility and Safety Study of MDMA-Assisted Group Therapy for the Treatment of Posttraumatic Stress Disorder in Veterans (MPG1)
On April 15, 2022, the U.S. Food and Drug Administration (FDA) upheld a partial clinical hold on Study MPG1, preventing the study from being initiated. FDA did not address specific questions from the previous …
MDMA Therapy Training Program Update: April 2022
In April 2022, we launched our first 100-hour blended (online/in person) training program and hosted a week-long in-person training retreat in North Carolina (pictured above). We welcomed over 75 trainees …
Long-Term Follow Up Study of MDMA-Assisted Therapy for PTSD
Enrollment is continuing for our long-term follow up study for our MDMA-assisted therapy parent studies. The long-term follow up study is open to individuals who participated and received MDMA in at least …
